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Purpose: To evaluate the optimal tracer uptake time, the minimal amount of radioactivity and the inter-observer
agreement for 11C-choline positron emission tomography/computed tomography (PET/CT) in patients with primary
hyperparathyroidism (pHPT).
Methods: Twenty-one patients with biochemically proven pHPT were retrospectively studied after injection of
6.3 ± 1.2 MBq/kg 11C-choline. PET data of the first nine patients, scanned for up to 60 min, were reconstructed
in 10-min frames from 10- to 60-min postinjection (p.i.), mimicking varying 11C-choline uptake times.
Parathyroid adenoma to background contrast ratios were calculated and compared, using standardized uptake
values (SUVs). Data was reconstructed with varying scan durations (1, 2.5, 5, and 10 min) at 20–30-min p.i.
(established optimal uptake time), mimicking less administered radioactivity. To establish the minimal required
radioactivity, the SUVs in the shorter scan durations (1, 2.5, and 5 min) were compared to the 10-min scan
duration to determine whether increased variability and/or statistical differences were observed. Four
observers analyzed the 11C-choline PET/CT in four randomized rounds for all patients.
Results: SUVpeak of the adenoma decreased from 30 to 40 p.i. onwards. All adenoma/background contrast
ratios did not differ from 20- to 30-min p.i. onwards. The SUVs of adenoma in the scan duration of 1, 2.5,
and 5 min all differed significantly from the same SUV in the 10-min scan duration (all p = 0.012). However,
the difference in absolute SUV adenoma values was well below 10% and therefore not considered clinically
significant. The inter-observer analysis showed that the Fleiss’ kappa of the 1-min scan were classified as
“moderate,” while these values were classified as “good” in the 2.5-, 5-, and 10-min scan duration. Observers
scored lower certainty scores in the 1- and 2.5-min scans compared to the 5- and 10-min scan durations.
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Conclusion: The optimal time to start PET/CT scanning in patients with pHPT is 20min after mean injection of 6.3
MBq/kg 11C-choline, with a recommended scan duration of at least 5 min. Alternatively, the radioactivity dose can be
lowered by 50% while keeping a 10-min scan duration without losing the accuracy of 11C-choline PET/CT
interpretation.
Keywords: Primary hyperparathyroidism, 11C-Choline PET, Inter-observer agreement, Scan protocolBackground
Primary hyperparathyroidism (pHPT) is a common endo-
crine disorder, with the highest incidence in elderly fe-
males (> 70 years) [1]. Eighty to 90% of pHPT is caused by
a single parathyroid adenoma [2]. Surgery, preferably a
unilateral minimally invasive parathyroidectomy (MIP), is
the only curative treatment.
To perform a MIP successfully, accurate preoperative im-
aging is essential. Worldwide, the current primary pre-
operative localization imaging standard consists of cervical
ultrasonography (cUS) combined with 99mTc-methoxyiso-
butylisonitrile-single-photon emission computed tomog-
raphy/(computed tomography) (MIBI-SPECT/(CT)) [3, 4]
reaching a sensitivity of 80–95% [5–7]. For the remaining
5–20% of patients, a full neck exploration is still necessary.
Lately, new functional imaging techniques using positron
emission tomography (PET)/CT, with, e.g., 11C-methionine
[8, 9] as radiotracer, have been studied, but no ideal PET
tracer for adenomas has emerged so far. Recently, 11C/18F-
choline was reported for visualization of adenomas and fa-
vorable results have been published in literature [10–15].
The physiology behind the uptake of 11C/18F-choline is un-
known, but may be based on the elevated concentration of
phosphatidylcholine in parathyroid cells [16].
So far, only one study has investigated the clinical per-
formance of 11C-choline PET/CT in patients with pHPT
[13]. Because 11C-choline is a relatively new technique
in patients with pHPT, the optimal uptake time of the
tracer and minimal injected radioactivity needs to be fur-
ther defined. To fulfill the need of routine clinical prac-
tice, consistency in the interpretation between different
observers is essential.
Therefore, this study aimed to optimize the scan
protocol, by assessing the optimal scanning time of 11C-
choline in combination with the minimal amount of
radioactivity needed for clinically acceptable image qual-
ity. Also, we studied the inter-observer agreement of
11C-choline PET/CT for the detection of parathyroid ad-
enomas in patients with pHPT.Material and methods
Study design and patients
This is a single-center retrospective cohort study of pa-
tients with biochemically proven pHPT who underwent
preoperative localization of the suspected parathyroidadenoma using 11C-choline PET/CT in a tertiary referral
hospital.
The medical charts of all patients who underwent 11C-
choline PET/CT between April 2015 and February 2017
were reviewed. Patients eligible for inclusion were those ≥
18 years, diagnosed with biochemically confirmed pHPT,
and who underwent 11C-choline PET/CT for the
localization of the suspected adenoma. In total, 23 patients
underwent 11C-choline PET/CT for the localization of an
adenoma. All patients had biochemically confirmed pHPT
(calcium and PTH values above the upper limit of nor-
mal). However, one patient was known to have multiple
endocrine neoplasia type I, and one patient was diagnosed
with familial hypocalciuric hypercalcemia (FHH); these
two patients were excluded from this analysis. Of the ana-
lyzed patients that were operated (67%), the 11C-choline
PET/CT correctly identified the location of the adenoma
in all cases. Of the analyzed patients that were not oper-
ated (33%), the 11C-choline PET/CT was positive in all
but one patient. This patient was only included in the
inter-observer analysis of this study and not in the analysis
of the optimal uptake time of the tracer and the radio-
activity to be administered (data not shown).
The medical charts were reviewed to determine the
injected activity of 11C–choline in MBq, gender, age, length,
weight, preoperative PTH, and corrected calcium (for cal-
culation of corrected calcium refer to Additional file 1).
Data obtained from patient records were anonymously
stored using study-specific patient codes in a password-
protected database. The study was exempt for collection
of informed consent after reviewing by the Medical Eth-
ics Committee Groningen (registration number 2016/
413).11C-Choline PET/CT
11C-choline was produced on site as described in [17].
Further details on production, patient preparation, and
PET/CT acquisition can be found in Additional file 2. In
the first nine patients, PET/CT images were taken dir-
ectly after injection of 7.0 ± 0.5MBq/kg [range 6.1–7.4
MBq/kg] 11C-choline for up to 40 to 60 min postinjec-
tion (p.i.). After an interim analysis of the first nine
patients had been performed to determine the most suit-
able uptake time of the tracer to reduce overall scan dur-
ation, all subsequent patients were scanned dynamically
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[range 4.2–8.5MBq/kg] for a duration of 10 min.
11C-Choline PET/CT analysis
Of the first nine patients, the images were reconstructed
in time frames of 10 min (0–10 to 50–60-min p.i.) to de-
termine the optimal uptake time of the tracer. Also,
these images were reconstructed in scan durations of 5
min (20–25 and 25–30 min), 2.5 min (20–22.5 to 27.5–
30min), and 1 min (20–21 to 29–30min) to assess
image quality as a function of scan duration used as a
surrogate for variation in administered radioactivity.
For each of these newly created images, accumulated
activity of 11C-choline in the adenoma was (semi) quan-
titatively evaluated by placing an automatic volume of
interest (VOI) with a threshold of 50% of the maximum
tracer uptake in the lesion, using an in-house software
(ACCURATE) [18]. In the surrounding normal back-
ground tissues (descending aorta, thyroid, shoulder
muscle, and the first thoracic vertebrae (T1)), a spherical
or cubical VOI, with a fixed size, was positioned. In the
thyroid gland, the cubical VOI was positioned in an area
on the contralateral side of the adenoma in healthy
appearing thyroid tissue. VOI’s were copied and trans-
ferred to scans of all time frames through an automatic
linking feature and manual correction if needed. In each
of these newly created images, peak, mean, and max-
imum standardized uptake values corrected for body
weight (SUVpeak, SUVmean, and SUVmax) were obtained
for adenoma and background organs: descending aorta,
thyroid, shoulder muscle, and T1. SUVmax represents
the maximum tracer uptake seen across all voxels within
the volume of interest. SUVpeak represents the average
uptake in a 1 mL spherical volume of interest positioned
such to yield the highest value across all possible loca-
tions of the lesion (or organ volume of interest). SUV-
mean is the mean SUV within the volume of interest.
SUVmean was used for analysis of the background tissues,
because it provides the most accurate and precise SUV
in case of regions with an almost uniform uptake, and
SUVpeak was used for the adenoma being the preferred
SUV metric to quantify tracer uptake in (small) lesions
besides SUVmax [19]. Moreover, SUVmax was used for all
as this metric is and has been used frequently and is
therefore included to allow comparison with other
studies.
Inter-observer agreement
All patients were included in the inter-observer agree-
ment analysis. The acquired image data at 20-min p.i.
was post-processed with varying scan duration of 1, 2.5,
5, and 10 min, respectively.
From all patients, two scans with a scan duration of 1
min and 2.5 min, both scans with a duration of 5 min,and the scan with a duration of 10 min were randomly
selected.
Four observers visually interpreted the scans in four
rounds, with increasing scan duration per round. Ob-
servers were asked to identify and localize any abnor-
mally increased 11C-choline uptake and to localize it in
the right upper, left upper, right lower, left lower, or ec-
topic zones. Next, in case of a focal increased uptake,
per location, they had to score how certain they were
that the uptake was indeed increased (certainty of in-
creased uptake (CIU)) and how certain they were that
the uptake could be attributed to an adenoma (certainty
of adenoma (CA)). They completed a standard scoring
form per patient, per round including a 5-point scale to
score their CIU and CA, with “1” being totally unsure
and “5” being totally sure. Further details of the inter-
observer analysis and assessment can be found in
Additional file 3.
Statistical analysis
Patient characteristics are described using means and
standard deviations (SD) or medians and ranges for con-
tinuous variables (depending on normal distribution).
All statistical analyses were performed with IBM SPSS
Statistics for Windows, Version 23.0 (Armonk, NY: IBM
Corp.). P values of < 0.05 were considered statistically
significant. For multiple testing, the Bonferroni correc-
tion was applied. Graphics were generated using Graph-
Pad Prism, Version 7.02 (La Jolla, CA, USA).
Optimal uptake time of tracer
Of the first nine patients, scanned for up to 40 to 60
min, contrast ratios (adenoma to muscle, T1, aorta, and
thyroid tissue) were calculated to determine the optimal
uptake time of the tracer. Contrast ratios were calculated
by dividing the SUVpeak for the adenoma by the SUVmean
for the background. The ratios in every time frame were
compared with the ratios in the upcoming time frame
using the Wilcoxon signed-rank test as normality of the
data could not be shown.
The SUVmean for thyroid and SUVpeak for adenoma (of
the first nine patients) in every uptake time were com-
pared with the same SUVs in the upcoming uptake time
using the Wilcoxon signed-rank test as normality of the
data could not be shown. Using the Bonferroni correc-
tion, p values < 0.01 were considered statistically
significant.
Radioactivity to be administered
In the analysis of the radioactivity to be administered,
only the first eight patients (scanned for up to 40 to 60
min) were included, since no post-processed images
could be made in scan durations of 1, 2.5, and 5 min for
one patient, because the original raw data was no longer
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ation of 10 min was, however, still available.
To assess the effect of injected radioactivity on SUV-
max, SUVmean, and SUVpeak for adenoma and background
tissues, the SUVs in the shorter scan durations (1, 2.5,
and 5 min) were compared to the 10-min scan duration
(at the determined optimal uptake time) to determine
whether statistical differences were observed, using the
Wilcoxon signed-rank test as normality of the data could
not be shown. For these analyses, the average SUVs of
patients per scan duration were calculated, since the 1-,
2.5-, and 5-min scan durations had multiple measure-
ments of SUV (10, 4, and 2, respectively) and the 10-
min scan duration only had 1 measurement. In this way,
we could assess if using different scan durations would
result in different SUV data, on average, i.e., if it would
result in a systematic bias. Using the Bonferroni correc-
tion, p values < 0.017 were considered statistically
significant.
Inter-observer agreement
Inter-observer agreement was calculated per possible lo-
cation (right upper, left upper, right lower, left lower, ec-
topic) by comparing the results of the location of theTable 1 Patients’ baseline and 11C-choline PET/CT scan characteristi








1 F 68 75 1.68 9.3 2.54
2 F 51 81 1.78 8.9 2.81
3 F 52 87 1.69 7.9 2.60
4 F 47 65 1.65 17.5 2.73*
5 F 65 75 1.72 8.8 2.67
6 F 74 92 1.60 28.0 3.10
7 M 36 73 1.83 47.0 2.93
8 M 53 80 1.81 10.0 2.69
9 F 63 89 1.72 8.3 2.68
10 F 69 90 1.78 18.0 2.72
11 M 60 72 1.78 14.0 2.62
12 M 83 93 1.82 10.0 2.65*
13 F 71 64 1.69 15.0 2.56
14 F 72 52 1.61 11.3 2.94
15 F 60 79 1.79 9.0 2.79*
16 F 68 53 1.61 27.1 3.00
17 F 53 70 1.70 11.3 2.94*
18 F 63 67 1.75 9.1 2.61
19 F 63 67 1.64 16.4 2.62
20 M 68 90 1.70 10.3 2.73*
21 M 69 102 1.84 15.0 2.59
F female, M male, p.i. postinjection
*only non-corrected calcium level was availableadenoma using the Fleiss’ kappa. Interpretations of the
kappa values were as follows: < 0.00 poor, 0.00–0.20
slight, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80
good, and > 0.81 almost perfect agreement [20].Results
Patient and scan characteristics
A total of 21 patients (15 females and 6 males) was in-
cluded in this study, with a mean age of 62 years [range
36–83] and a mean administered activity of 6.3 ± 1.2
MBq/kg [range 4.2–8.5MBq/kg] (Table 1).11C-Choline PET/CT analysis
Optimal uptake time of tracer
The SUVmean for thyroid initially decreased before level-
ing off from 20- to 30-min p.i. onwards, while the SUV-
peak for adenoma was constant until 30–40-min p.i. and
decreased afterwards (Fig. 1) (Table 2). We found no sig-
nificant differences between the SUVpeak for adenoma
for the different uptake times (p > 0.110). There were
significant differences between the SUVmean for thyroid
in the uptake time of 0–10 versus 10–20min (p = 0.008)







Directly p.i. 60 min 7.2
Directly p.i. 60 min 6.1
Directly p.i. 40 min 7.3
Directly p.i. 50 min 7.4
Directly p.i. 60 min 7.0
Directly p.i. 50 min 7.3
Directly p.i. 60 min 7.0
Directly p.i. 60 min 7.1
Directly p.i. 40 min 6.2
20-min p.i. 10 min 4.6
20-min p.i. 10 min 5.6
20-min p.i. 10 min 4.3
20-min p.i. 10 min 6.7
20-min p.i. 10 min 8.5
20-min p.i. 10 min 5.3
20-min p.i. 10 min 7.5
20-min p.i. 10 min 5.6
20-min p.i. 10 min 6.6
20-min p.i. 10 min 6.9
20-min p.i. 10 min 4.6
20-min p.i. 10 min 4.2
Table 2 Descriptive statistics of the SUVs for thyroid and
adenoma for the different uptake times in n = 9 patients
Uptake time of tracer (min)
00–10 10–20 20–30 30–40 40–50 50–60
SUVmean thyroid
Median 3.41 2.38 2.20 2.32 1.95 2.18
SD 0.97 0.72 0.65 0.62 0.55 0.45
IQ 1.02 1.21 1.13 1.06 0.99 0.86
SUVpeak adenoma
Median 4.19 4.22 4.11 4.36 3.38 3.25
SD 2.24 2.39 2.46 2.58 3.10 1.64
IQ 3.16 3.19 2.93 2.70 3.03 2.97
SD standard deviation, IQ interquartile range, SUV standardized uptake value
Only 7 and 5 patients were scanned until 50 and 60 min, respectively
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ferences in the SUVmean for thyroid (p > 0.018).
We focused on the adenoma/thyroid contrast ratio, as
the adenoma is usually closest located to the thyroid,
refer to Additional file 4 for data on adenoma/aorta, ad-
enoma/muscle and adenoma/T1 contrast ratios.
The adenoma/thyroid ratio became constant from
the uptake time of 20–30-min p.i. onwards (Fig. 2).
In the uptake time of 0–10 versus 10–20-min p.i., the
adenoma/thyroid ratio increased from 1.49 to 1.65
(p = 0.008) (Table 3). In the uptake time of 10–20 ver-
sus 20–30 min, the adenoma/thyroid ratio (increase
from 1.65 to 1.85) is just slightly beyond the level of
significance (p = 0.028). From the uptake time of 20–
30-min p.i. onwards, there were no significant differ-
ences with upcoming uptake times for any ratio and
p values were higher compared to previous uptake
times (p > 0.043).Radioactivity to be administered
The SD and interquartile range (IQ) of SUVpeak for
adenoma, SUVmean for background tissue, and SUV-
max for all locations decreased with increasing scan
duration (Table 4 and Additional file 5). The SUVpeak
for adenoma and SUVmean for background tissue var-
ied less than SUVmax, as witnessed by higher SD and
IQ for SUVmax for each scan duration (Table 4 and
Additional file 5).
In addition, all individual SUVs in the scans with a
duration of 1 min seemed more variable than the SUVs
in the scan duration of 2.5, 5, and 10 min (Fig. 3, Table 4,
and Additional file 5).a
Fig. 1 Scatter plot of SUVs for parathyroid adenoma and thyroid in n = 9 p
b SUVmean of the thyroid. SUV standardized uptake value, Uptake time of tra
acquisition, *significant difference (p < 0.01). Only 7 and 5 patients were scaThere was no significant difference in SUVmean for thy-
roid between the different scan durations (all p = 0.674),
whereas there was a significant difference in SUVmax for
thyroid between a 1-min versus 10-min scan duration and
a 2.5-min versus 10-min scan duration (both p = 0.012).
There was no difference in SUVmax for thyroid between a
5-min versus 10-min scan duration (p = 0.069). The SUVs
for adenoma in the scan duration of 1, 2.5, and 5min all
differed statistically from the same SUV in the 10-min
scan duration (all p = 0.012).
Inter-observer agreement
In total, 141 scans were used for this analysis. Figure 4
shows a typical example of a 11C-choline PET/CT scan
with 1-, 2.5-, 5-, and 10-min scan duration. The kappa
values in the scan durations of 2.5, 5, and 10min were
good, while it was “moderate” in the scan duration of 1b
atients. Scatter plots with median values of a SUVpeak of the adenoma.
cer time (in min) between injection of 11C-choline and start of PET/CT
nned until 50-min and 60-min postinjection, respectively
Fig. 2 Scatter plot of parathyroid adenoma to thyroid contrast ratios in n = 9 patients. Scatter plot with median values of adenoma/thyroid ratio.
Uptake time of tracer time (in min) between injection of 11C-choline and scanning procedure, *significant difference (p < 0.01). Only 7 and 5
patients were scanned until 50-min and 60-min postinjection, respectively
Table 4 Descriptive statistics of the average SUVs for adenoma
and thyroid for the different scan durations in n = 8 patients
SUVpeak for adenoma SUVmean for thyroid
Scan duration (min) Scan duration (min)
1 2.5 5 10 1 2.5 5 10
Median 3.88 3.81 3.80 3.71 Median 2.10 2.11 2.11 2.15
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the certainty score of positive identified lesions, in-
creased with increasing scan duration (Table 6).
Discussion
In this study, we evaluated the scan protocol and inter-
observer agreement of 11C-choline PET/CT in patients
with biochemically confirmed pHPT. We found that the
optimal uptake time of 11C-choline PET/CT scanning is
20 min, since from 20-min p.i. onwards the adenoma/
background contrast ratios and SUVmean for thyroid be-
came constant.
In addition, we quantitatively analyzed various scan
durations as a surrogate for injecting different amounts
of radioactivity. Although there was a significant differ-
ence in (average) SUVs at shorter scan durations com-
pared to the 10-min scan, the differences for the 2.5-
and 5-min scan durations were small, well below 10%,
and clinically not relevant given the spread in the ob-
served SUV values. However, the observed increasedTable 3 Descriptive statistics of the adenoma/thyroid ratios for
the different uptake times in n = 9 patients
Uptake time of tracer (min)
00–10 10–20 20–30 30–40 40–50 50–60
Median 1.49 1.65 1.85 1.95 2.01 1.98
SD 0.78 1.09 1.20 1.21 1.46 .52
IQ 0.61 0.59 0.61 0.64 0.91 0.95
SD standard deviation, IQ interquartile range
Only 7 and 5 patients were scanned until 50 and 60 min, respectivelyspread in SUV values for the 1-min scan duration was
wider compared with the other scan durations. There-
fore, we advise for quantitative analysis not to lower the
scan duration beyond 2.5 min.
To evaluate the clinical relevance of images with dif-
ferent quality, we performed an inter-observer study re-
garding lesion detection and localization. We concluded
that a 1-min scan is too short for accurate visual inter-
pretation of 11C-choline PET/CT images. The certainty
scores (CIU and CA) were generally lower in the 1-min
and 2.5-min scan durations compared to the 5- and 10-
min scan durations. In clinical routine, it may occur thatSD 2.70 2.69 2.67 2.61 SD 0.69 0.69 0.69 0.68
IQ 3.41 3.43 3.44 3.34 IQ 0.96 0.97 0.96 0.99
SUVmax for adenoma SUVmax for thyroid
Scan duration (min) Scan duration (min)
1 2.5 5 10 1 2.5 5 10
Median 6.74 6.47 6.41 6.24 Median 3.11 2.93 2.87 2.84
SD 4.06 3.98 3.89 3.71 SD 0.94 0.97 0.98 0.96
IQ 6.54 6.54 6.58 5.85 IQ 1.62 1.59 1.56 1.54
SD standard deviation, IQ interquartile range, SUV standardized uptake value
a b
Fig. 3 Scatter plot of SUVmean, SUVpeak, and SUVmax of adenoma and thyroid in the different scan durations (1, 2.5, 5, and 10 min) in n = 8
patients. Scatter plot representing median values and interquartile ranges of a SUVpeak for adenoma and SUVmean for thyroid in the different scan
durations. b SUVmax for adenoma and thyroid in the different scan durations. SUV standardized uptake value, *significant difference (p < 0.017)
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tered to the patient, e.g., due to a lower production at
the radiochemistry lab or to paravasal injection. Also,
adenomas can be very small structures. Therefore, com-
bining the results of the quantitative and inter-observer
data, we recommend to establish a safety margin for
11C-choline PET/CT scanning with 6.3 MBq/kg and scan
for at least 5 min. Alternatively, the radioactivity dose
can be lowered by 50% while maintaining a 10-min scan
duration.
As can be expected, we found that the SUVpeak is less
variable than the SUVmax. This is consistent with find-
ings for FDG PET/CT in oncology, as shown by Lodge
et al. and Makris et al. [21, 22]. In these studies, it was
observed that SUVmax is more sensitive to noise, show-
ing increased variability and upward bias as compared to
SUVpeak. The latter can be understood as SUVmax repre-
sents the uptake in a single voxel, while SUVpeak is de-
rived from a 1mL spherical volume of interest thereby
mitigating the effects of image noise. Therefore, if the
radioactivity in the adenoma needs to be quantified, it is
best to use the SUVpeak for parathyroid tracer uptake
quantification as it shows a better precision than
SUVmax.
SUVs in the blood pool are known to be relatively low,
and thus, these regions suffer from poor count statistics.
SUVmax for the aorta in the 1-min scan duration was
higher than those seen at longer scan durations. This
can be expected because SUVmax is more sensitive tonoise and thus showing upward biases with increased
noise levels [21, 22].
Quantitative research on the scan protocol for para-
thyroid imaging with PET/CT is very limited. The opti-
mal scan time for 18F-choline PET/CT in pHPT has
been investigated once before by Rep et al. 18F has a
considerable longer half-life of 110 min, compared to 20
min for 11C. Rep et al. only focused on an uptake time
of 5 min, 60 min, or 2 h. They found that the optimal
scan time of 18F-choline PET/CT for localization of en-
larged parathyroid tissue is 1 h after administration [23].
In the current study with 11C-choline, we focused on the
interval between 5 and 60 min. Prabhu et al. also investi-
gated the utility of an early dynamic PET/CT in detect-
ing parathyroid lesions, but they performed it for the
tracer 18F-choline. They found that early dynamic 18F-
choline PET/CT imaging could suffice, without the need
for a delayed image after 45 min [24]. This is more in
line with the optimal uptake time of 20 min found in
our study for 11C-choline.
Our retrospective study has limitations. We assumed
that all lesions that were identified on the 11C-choline
PET/CT were parathyroid adenomas in this group of pa-
tients with biochemically proven pHPT, although we
only have surgical and pathological confirmation in two
thirds of the patients (data not shown). Since our study
focuses on the technical aspects of lesion detectability,
and because determining the sensitivity of this type of
PET/CT scan for correct localization of an adenoma was
Fig. 4 11C-Choline PET/CT images of a patient with a parathyroid adenoma 20-min p.i. with varying acquisition times. a Transverse PET image of
1-min acquisition, b 2.5-min acquisition, c 5-min acquisition, and d 10-min acquisition. a and b appear “noisier” than c and d. e Corresponding
transverse image of low-dose CT, and f PET/CT fusion image with 5-min PET acquisition time. g Maximum Intensity Projection (MIP) PET image of
5-min acquisition at 20-min postinjection images of patient number 1 (Table 1). Note the physiological uptake in the salivary glands, and
remaining activity in the vessel used for injection of the tracer. Also, slight uptake is seen in a thyroid nodule in the left thyroid lobe
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jective final surgical and pathological outcome is less
crucial.
In our retrospective study, we chose to use SUV cor-
rected for body weight, as this is the SUV type most
used. No efforts were made to relate optimal dose to
length, weight, or BMI. The latter would require a phar-
macokinetic study including arterial sampling to assess
which SUV normalization corresponds best with full
quantitative pharmacokinetic results. This was beyond
the scope of this study, and therefore, the most standard
metric was chosen of SUV corrected for body weight.
Yet, when analyzing the data using lean body mass (data
not shown), results were very comparable and did not
affect conclusions. Moreover, the sample size is tooTable 5 Results of inter-observer agreement of n = 4 observers
for the different scan durations in n = 21 patients
1 min 2.5 min 5 min 10 min
Fleiss’ kappa location 0.553 0.687 0.656 0.674small to fully assess the relationship and the interactions
between these parameters. Larger datasets are required
for further refinement or dose optimization. Yet, at
present, our study demonstrated that we can safely re-
duce scan duration or activity dose with a factor of two
without compromising visual image interpretations. The
authors acknowledge, however, that investigation of fur-
ther dose refinements is of interest.
Always the same researcher quantified the 11C-choline
PET/CT scans by placing the VOIs in the adenoma and
background. Another researcher would probably find
slightly different SUVs. To better estimate this standard
error, we tested whether the SUVmean was different if we
moved the square VOI of the thyroid 2 voxels up or
down. In the 10-min scan durations, the median differ-
ence was 3.32% with a standard deviation of 8.33%,
which we consider acceptable low (data not shown).
Other limitations were encountered in the inter-
observer part of the study. The working experience for
the observers differed, and two of the observers had lim-
ited experience with 11C-choline PET/CT for the
Table 6 Descriptive statistics of the CIU and CA per observer (n = 4), only representing the certainty score of positive identified
lesions, for the different scan durations in n = 21 patients
Scan duration of 1 min Scan duration of 2.5 min
Obs1 Obs2 Obs3 Obs4 Obs1 Obs2 Obs3 Obs4
Mean CIU 3.54 2.56 4.55 4.40 Mean CIU 4.09 2.89 4.51 4.18
SD CIU 1.36 0.97 0.67 1.06 SD CIU 0.97 1.09 0.71 0.97
Range CIU 4 3 2 4 Range CIU 4 4 2 3
Mean CA 3.42 2.22 3.74 3.60 Mean CA 3.30 2.59 4.27 3.85
SD CA 1.30 1.01 1.36 1.24 SD CA 1.40 1.08 1.15 1.35
Range CA 4 3 4 4 Range CA 4 4 4 4
Scan duration of 5 min Scan duration of 10 min
Obs1 Obs2 Obs3 Obs4 Obs1 Obs2 Obs3 Obs4
Mean CIU 4.21 4.00 4.77 3.94 Mean CIU 4.40 4.19 4.41 3.95
SD CIU 1.02 0.96 0.49 1.39 SD CIU 0.91 0.91 0.85 1.50
Range CIU 3 3 2 4 Range CIU 3 3 2 4
Mean CA 3.92 3.44 4.26 3.29 Mean CA 4.00 3.69 4.27 3.10
SD CA 1.25 1.01 1.31 1.47 SD CA 1.25 0.95 0.88 1.65
Range CA 4 3 4 4 Range CA 4 3 2 4
CIU certainty increased uptake, CA certainty adenoma, Obs observer, SD standard deviation
Noltes et al. EJNMMI Research            (2019) 9:73 Page 9 of 10identification of adenomas. Despite these limitations, the
inter-observer agreement for the scan duration of 2.5, 5,
and 10min qualified as “good.”
Conclusion
This study optimizes the protocol for parathyroid 11C-
choline PET/CT imaging, potentially resulting in less
radioactivity injected into patients. We showed that, tak-
ing into account both quantitative performance and
image quality, the optimal time to start PET/CT scan-
ning in patients with pHPT is 20 min after mean injec-
tion of 6.3MBq/kg 11C-choline, with a recommended
scan duration of at least 5 min. Alternatively, the radio-
activity dose can be lowered by 50% while maintaining a
10-min scan duration without losing accuracy of 11C-
choline PET/CT interpretation.
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